EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring...

Descripción completa

Detalles Bibliográficos
Autores principales: Nan, Xueli, Xie, Chao, Yu, Xueyan, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650459/
https://www.ncbi.nlm.nih.gov/pubmed/29088904
http://dx.doi.org/10.18632/oncotarget.20095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650459/
https://www.ncbi.nlm.nih.gov/pubmed/29088904
http://dx.doi.org/10.18632/oncotarget.20095

Ejemplares similares